- Home
- AMRN vs BCYC Comparison
AMRN vs BCYC Comparison
Compare AMRN & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | BCYC |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | Ireland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.9M | 291.8M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AMRN | BCYC |
|---|---|---|
| Price | $14.04 | $3.83 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $12.00 | ★ $13.90 |
| AVG Volume (30 Days) | 79.6K | ★ 280.1K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.22 | N/A |
| 52 Week Low | $12.96 | $3.75 |
| 52 Week High | $20.90 | $9.16 |
Technical Indicators
Market Signals| Indicator | AMRN | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 37.80 |
| Support Level | $13.59 | N/A |
| Resistance Level | $14.55 | $4.51 |
| Average True Range (ATR) | 0.54 | 0.18 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 36.25 | 0.73 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.